Documents

Pneumococcal AMC: OECD GDP Deflator Data Purpose: As per the Pneumococcal AMC Inflation Review Application Process, listed below is the OECD GDP Deflator to be used to calculate an inflation adjustment request. BASE QTR Q2-2009 Q2-2010 Q2-2011 Q2-2012 Q2-2013 Q2-2014 Q2-2015 Q2-2016 Q2-2017 Q2-2018 Q2-2019 Q2-2020 Q2-2

Addressing the environmental impact of GAVI-supported immunisation activities.

ŀ GAVI ALLIANCE EVALUATION OF GAVI SUPPORT TO CSOS 17 January 2012 EVALUATION REPORT Prepared by: CEPA LLP CONTENTS Acronyms and abbreviations ................................................................................................ i Executive summary ............................................................

GAVI ALLIANCE EVALUATION OF GAVI SUPPORT TO CIVIL SOCIETY ORGANISATIONS 17 January 2012 COUNTRY EVALUATION REPORT -INDONESIA Prepared by: Cambridge Economic Policy Associates LLP ii CONTENTS Acronyms and abbreviations .............................................................................................. iii Exe

1 EVALUATION OF GAVI SUPPORT TO CSOs Management Response – September 2012 Theme Recommendation Management Response Timeline/Responsibility Structure of GAVI CSO Support Focus of the support 1. GAVI CSO support should be restructured as a ‘single funding stream’ rather than two separate types of support. The focus shoul

GAVI ALLIANCE EVALUATION OF GAVI SUPPORT TO CIVIL SOCIETY ORGANISATIONS 17 January 2011 COUNTRY EVALUATION REPORT -AFGHANISTAN Prepared by: Drs. Kayhan Natiq & Essa Tawfiq with support from: Cambridge Economic Policy Associates LLP ii CONTENTS Acronyms and abbreviations .................................................

ŀ GAVI ALLIANCE EVALUATION OF GAVI SUPPORT TO CSOS 17 January 2012 EVALUATION REPORT (ANNEXES) Prepared by: CEPA LLP CONTENTS Annex 1: Glossary.................................................................................................................. 1 Annex 2: Bibliography and data sources .....................

ŀ GAVI ALLIANCE EVALUATION OF GAVI SUPPORT TO CSOS 3 February 2012 RECOMMENDATIONS PAPER Prepared by: CEPA LLP CONTENTS Acronyms and abbreviations ................................................................................................ i 1. Introduction ..........................................................

ŀ GAVI ALLIANCE EVALUATION OF GAVI SUPPORT TO CIVIL SOCIETY ORGANISATIONS 17 January 2012 COUNTRY EVALUATION REPORT -DRC Prepared by: Eliot Putnam, CEPA Associate and Cambridge Economic Policy Associates LLP ii CONTENTS Acronyms and abbreviations .........................................................................

GAVI ALLIANCE EVALUATION OF GAVI SUPPORT TO CIVIL SOCIETY ORGANISATIONS 17 January 2012 COUNTRY EVALUATION REPORT -PAKISTAN Prepared by: Anita Zaidi with specific inputs from Ayesha Khan and support from: Cambridge Economic Policy Associates LLP ii CONTENTS Acronyms and abbreviations ...................................

GAVI ALLIANCE EVALUATION OF GAVI SUPPORT TO CIVIL SOCIETY ORGANISATIONS 17 January 2012 COUNTRY EVALUATION REPORT -ETHIOPIA Prepared by: Cambridge Economic Policy Associates LLP ii CONTENTS Acronyms and abbreviations .............................................................................................. iii Exec

Collection of documents designed to provide GAVI-eligible countries with details of two new modalities of support available through the Health Systems Funding Platform (the Platform).

ACCELERATE VACCINE INTRODUCTION – PNEUMOCOCCAL CONJUGATE VACCINE Strategic Demand Forecast (Required Supply) Version 5.0 – updated in March 2012 Published – 13 August 2012 This version 5.0 is issued in accordance with the AVI Forecasting Standard Operating Procedure.

This report presents the findings and lessons learnt from a review of the Accelerated Vaccine Introduction (AVI) Project undertaken by Cambridge Economic Policy Associates (CEPA) for the GAVI Alliance. The review period spans from February to June 2012.

Annexes to report presenting the findings and lessons learnt from a review of the Accelerated Vaccine Introduction (AVI) Project. The review period spans from February to June 2012.

Remaining AMC offer amount: June 2012

Frequently asked questions about GAVI's co-financing policy for country applicants.

The 2012 Pneumococcal AMC Annual Report gives an overview of all activities linked to the implementation of the pilot Advance Market Commitment from 1 April 2011 to 31 March 2012. It provides an extensive description of the first achievements of this innovative initiative: the first introductions of pneumococcal vaccines in GAVI countries.